The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the “Catastrophic antiphospholipid syndrome registry”

Abstract

Objectives

To explore the prevalence and clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome (CAPS).

Methods

We reviewed data from the “CAPS Registry” on C3 and/or C4 complement plasma protein levels during acute CAPS episodes. Patients were classified into those with low and normal complement levels. Data on clinical presentation, with special focus on thrombotic microangiopathy (TMA) features, diagnosis of systemic lupus erythematosus (SLE), and antiphospholipid antibody (aPL) profile were reviewed. The chi-square exact test was performed to evaluate differences between categorical data.

Results

The “CAPS Registry” includes 566 patients with a total of 578 episodes of CAPS. Data on complement plasma protein levels was available in 73 episodes from the same number of patients. Low levels of C3 and/or C4 complement plasma proteins were detected in 42 (58%) CAPS episodes. Low complement levels were more common in SLE patients (55% SLE vs. 19% No SLE; p<0.001). The frequencies of clinical TMA (72% vs. 80%; p=0.4) or TMA syndrome (86% vs. 84%, p=0.9), frequency of triple aPL triple positivity (67% vs 33%; p=0.3), or the mortality (35% vs. 31%; p=0.7) were similar between low and normal complement groups.

Conclusion

In our study, low levels of C3 and C4 plasma proteins are detected in 58% episodes of CAPS, which were not associated with clinical presentation including TMA features, aPL triple positivity, or mortality.

Keywords

complement antiphospholipid syndrome catastrophic antiphospholipid syndrome

Get full access to this article

View all access options for this article.

References

Cervera

. Antiphospholipid syndrome. Thromb Res 2017; 151(Suppl 1): S43–S71.

Asherson

Cervera

Piette

, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 Patient. Medicine (Baltimore) 1998; 77: 195–207.

Asherson

Cervera

Piette

, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 Patients. Medicine (Baltimore) 2001; 80: 355–377.

Ruffatti

Tarzia

Fedrigo

, et al. Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmun Rev 2019; 18: 561–563.

Chaturvedi

Braunstein

Yuan

, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135: 239–251.

Barratt-Due

Fløisand

Orrem

, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology (Oxford) 2016; 55: 1337–1339.

Skoczynska

Crowther

Chowaniec

, et al. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. Lupus 2020; 29: 631–639.

Asherson

Cervera

De Groot

, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530–534.

Hillmen

Young

Schubert

, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233–1243.

10.

Trouw

Pickering

Blom

. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 2017; 13: 538–547.

11.

Morgan

Harris

. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015; 14: 857–877.

12.

Ricklin

Lambris

. New milestones ahead in complement-targeted therapy. Semin Immunol 2016; 28: 208–222.

13.

Chaturvedi

Braunstein

Brodsky

. Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost 2021; 19: 607–616.

14.

Erkan

Espinosa

Cervera

. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10: 74–79.

15.

Cervera

Font

Gómez-Puerta

, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205–1209.

16.

Fajgenbaum

June

Longo

. Cytokine storm. N Engl J Med 2020; 383: 2255–2273.

17.

Wehling

Amon

Bommer

, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017; 187: 304–315.

18.

George

Nester

. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 654–666.

19.

Cervera

Serrano

Pons-Estel

, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011–1018.

20.

Cervera

Espinosa

. Update on the catastrophic antiphospholipid syndrome and the ‘CAPS registry. Semin Thromb Haemost 2012; 38: 333–338.

21.

Rodríguez-Pintó

Moitinho

Santacreu

, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 2016; 15: 1120–1124.

22.

Fargue

Ribes

. Early use of eculizumab for catastrophic antiphospholipid syndrome. Br J Hematol 2022; 196: e12–e14. DOI: 10.1111/bjh.17783

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB